GB-CP23

About GlycosBio

GlycosBio is a private, preclinical-stage biotech firm leveraging its proprietary lipid engineering platform to create Activated Oil Systems for enhanced drug delivery and microbiome modulation. Founded in 2007 and operating from the Texas Medical Center, the company follows an R&D and IP licensing business model, collaborating with clients to validate and commercialize technologies. Its pipeline includes clinical programs targeting atopic dermatitis, oral health (S. mutans), and pharyngitis, aiming to provide alternatives to antibiotics and broad-spectrum treatments.

Therapeutic Areas